In 2012, the World Trade Center Health Program recognized malignant neoplasm of the ovary (ovarian cancer) as a 9/11-caused cancer. While this was a landmark finding, much work remains to be done since ovarian cancer remains one of the most challenging cancers to treat, primarily when it is not detected early. Traditionally, the treatment of ovarian cancer involves a combination of surgery and platinum-based chemotherapy, which often affects healthy cells along with cancerous ones, and leads to adverse side effects among patients with ovarian cancer. Furthermore, outcomes for ovarian cancer cases not detected early have been poor, and most patients treated with chemotherapy go on to develop chemo-resistant ovarian cancer. Recent advancements in research and treatment, including more precise chemotherapies and targeted therapies, are providing new hope for patients, including those with an increased risk of ovarian cancer due to toxic exposure like those present in the aftermath of the September 11, 2001 attacks.
The most common type of ovarian cancer is high-grade serous ovarian adenocarcinoma, accounting for approximately 75% of epithelial ovarian cancers. Clear cell carcinoma is the second most common type of ovarian cancer and is seen in approximately 1 out of 10 women diagnosed with epithelial ovarian cancers. Other less common forms of epithelial ovarian cancer include endometrioid adenocarcinoma, mucinous adenocarcinoma, and low-grade serous carcinoma. Other rare types of ovarian cancer include stromal tumors, germ cell tumors, and small cell cancer of the ovary.